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Your critical care patient may have HLH
(hemophagocytic lymphohistiocytosis)
Rafal Machowicz1*, Gritta Janka2 and Wieslaw Wiktor-Jedrzejczak1
Among various actions taken to improve the prognosis
of critical care patients, an important step is including
hemophagocytic lymphohistiocytosis (HLH; hemophago-
cytic syndrome) in the differential diagnosis.
HLH is an uncontrolled, self-propelling hyperinflam-
mation. It can be initiated in a predisposed individual
by various triggering factors: infection (especially
viral, notably Epstein-Barr virus (EBV)), malignancy
(frequently by T-cell lymphoma), or autoimmune
disease. The triggering factor unleashes a positive
feedback loop with extremely high concentrations of
pro-inflammatory cytokines (“cytokine storm”) which
leads to multiorgan failure (MOF) and death. Only
timely proper diagnosis and treatment can reverse
this dismal outcome.
The cause of this rare, pathologic hyperinflammation
is an immune dysfunction, which in familial cases was
found to result from an inherited lack of cytotoxic activ-
ity of T cytotoxic and natural killer lymphocytes, which
retain the ability to release cytokines. A similar, but not
fully understood, mechanism is expected in the acquired
cases. Mutations in cytotoxic granule pathway genes
(e.g., Perforin, UNC13D or STX11) are the cause in fa-
milial HLH [1]. HLH was at first perceived as affecting
only infants with mutations in these specific genes, but
later the syndrome was also found in adolescents and
adults, so the term “secondary HLH” was coined. This
approach was abandoned because (regardless of age and
mutation status) all HLH episodes are thought to be sec-
ondary to a triggering factor (which cannot always be
identified). Nowadays, with a growing number of adult
patients of whom a considerable proportion harbor a
proven mutation in HLH-related genes (25 % [2], 14 %
[3]), the syndrome is considered as a continuum from
neonates with complete loss of cytotoxic function,
through adolescents to elderly adults with mutations
only partially affecting the cytotoxic activity or patients
without any characteristic mutation but with symptom-
atic HLH.
In most patients, in the absence of genetic traits, diagno-
sis of HLH is based on fulfillment of five out of eight HLH
2004 [1] criteria: 1) persistent fever; 2) splenomegaly; 3)
bicytopenia (hemoglobin <9 g/dl, neutrophils <1.0 × 109/l,
platelets <100 × 109/l); 4) hypofibrinogenemia (<150 mg/dl)
and/ or hypertriglyceridemia (>265 mg/dl); 5) hyperferriti-
nemia (>500 ng/ml); 6) hemophagocytosis; 7) low natural
killer cell activity; and 8) high concentration of sCD25
(soluble receptor for interleukin 2).
Hemophagocytosis occurs when activated macro-
phages phagocytose other blood or bone marrow cells.
Despite the name of the syndrome, hemophagocytosis is
neither necessary nor sufficient to diagnose HLH—it is
only one of the criteria. It is not an essential part of the
HLH pathomechanism, but rather develops in a more
advanced stage of the process [4]. Therefore, it can be
absent in patients with HLH, and it is also not pathog-
nomonic for this syndrome. Hemophagocytosis is a fre-
quent finding, especially in intensive care—it was
observed in 64 % of the ICU patients with sepsis and
thrombocytopenia [5] (32/50) and in 65 % deceased ICU
patients [6] (69/107). Diagnosis of HLH is possible with-
out bone marrow aspirate/biopsy; however, this proced-
ure should be performed to search for underlying
malignancy. Neoplasms are among the most important
HLH triggers in adults and are associated with a poor
prognosis [7].
The most important parameter, besides cytopenias,
characteristic for HLH is hyperferritinemia. The specific
(especially for ICU patients) values are much higher
than the HLH 2004 criterion and exceed 2000–3000 ng/
ml, reaching high specificity (but low sensitivity) above
10,000 ng/ml. All patients with such high ferritin values
should have other HLH criteria assessed. Indications for
ferritin testing are cytopenias and/or splenomegaly in a
febrile patient whose clinical status and laboratory values
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are worsening despite standard treatment with anti-
infectious therapy.
Although treatment of the trigger is important (if it is
possible at all), this is usually not sufficient to suppress
the high cytokine levels. Treatment modalities include
immunosuppressive/immunomodulatory agents such as
steroids, intravenous immunoglobulins, cyclosporine A,
removal of the cytokines by plasmapheresis, and, in se-
vere cases, etoposide [8]. A delay in etoposide treatment
was proven to have a negative impact on prognosis in
EBV-associated HLH [9]. Without immune suppression,
and despite all possible efforts of intensive care, HLH is
often fatal.
Raising the awareness of HLH—a life-threatening,
heavily underdiagnosed syndrome—is of paramount im-
portance, especially since the tests for preliminary diag-
nosis (ferritin concentration) and treatment (etoposide,
steroids, cyclosporine A) are relatively inexpensive and
widely available.
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